|
Phase I Study of Intrathecal Topotecan Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Phase I Study of Intrathecal Topotecan conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Phase I Study of Intrathecal Topotecan Clinical research trials and Phase I Study of Intrathecal Topotecan medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Phase I Study of Intrathecal Topotecan. Phase I Study of Intrathecal Topotecan Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Phase I Study of Intrathecal Topotecan clinical trial. Participants oftentimes recieve the finest healthcare available for their Phase I Study of Intrathecal Topotecan condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase I Study of Intrathecal Topotecan  Phase I Study of Intrathecal Topotecan
Phase I Study of Intrathecal Topotecan
For Condition: Leukemia,Lymphoma,Meningeal Neoplasms
Status: Completed
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: The purpose of this study is to determine the qualitative and quantitative toxicity of intrathecal topotecan, a topoisomerase I inhibitor, in patients with meningeal malignancies refractory to conventional therapy (radiation therapy and chemotherapy).
Details: The purpose of this study is to determine the qualitative and quantitative toxicity of intrathecal topotecan, a topoisomerase I inhibitor, in patients with meningeal malignancies refractory to conventional therapy (radiation therapy and chemotherapy). A safe dose of topotecan that can be recommended for intrathecal administration in subsequent phase II studies will be established in a limited dosage escalation schedule. The CSF pharmacokinetics of intrathecal topotecan will also be studied. Topotecan will be administered intrathecally on a bi-weekly basis for four to six weeks, followed by weekly administration for 1 month, twice monthly administration for four months and then monthly IT administration.
Eligibility:
Study Type: Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: Leukemia, lymphoma, or solid tumor with overt meningeal involvement considered refractory to conventional therapy. CSF leukemic cell count at least 5 per cubic millimeter with evidence of blast cells on cytospin or cytology required for leukemia and lymphoma patients. Tumor cells on cytospin or cytology or measurable meningeal disease on CT or MRI required for patients with solid tumors. No clinical evidence of obstructive hydrocephalus or compartmentalization of the CSF flow as documented by indium-111- or technetium-99-DPTA flow study. PRIOR/CONCURRENT THERAPY: At least 1 week since CNS therapy. Biologic Therapy: Recovery from toxic effects of prior immunotherapy required. Chemotherapy: Recovery from toxic effects of prior chemotherapy required. No concomitant therapy to treat meningeal malignancy (intrathecal or systemic). Concomitant chemotherapy to control systemic disease or bulk CNS disease allowed except: Investigational agents. Agents that penetrate the CNS (e.g., high-dose methotrexate, thiotepa, high-dose cytarabine, fluorouracil, intravenous mercaptopurine). Agents known to have serious unpredictable CNS side effects. Endocrine Therapy: Not specified. Radiotherapy: Recovery from toxic effects of prior radiotherapy required. Patient eligible if flow restored following focal radiotherapy to the blockage site. Surgery: Not specified. PATIENT CHARACTERISTICS: Age: 3 and over (older patients giving consent will be enrolled before the very young, if possible). Performance status: ECOG 0-2. Life expectancy: At least 8 weeks. Hematopoietic: See Disease Characteristics. Hepatic: Bilirubin less than 2.0 mg/dL, SGPT less than 3 times normal. Renal: Creatinine less than 1.5 mg/dL. Metabolic: Serum electrolytes (including calcium and phosphate) normal. Other: No significant systemic illness (e.g., infection). Not pregnant or lactating.
Total Enrollment: 30
Location and Contact Information:
National Cancer Institute (NCI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 930085; 93-C-0085
Study Start Date: February 4, 1993
Record last reviewed: January 1, 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001333
Other Leukemia Studies:
1. Phase I Study of Intrathecal Topotecan
2. DepoCyt Therapy in Patients with Neoplastic Meningitis from Lymphoma or a Solid Tumor
3. Phase I Study of Gemcitabine to Treat Cancer Spread to the Meninges
Related Studies:
Other Leukemia Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Phase I Study of Intrathecal Topotecan
|
|
|
|
|
|
|
|
